Rhythm Diagnostic Systems SA received CE mark approval from EU authorities for Multisense, a wearable device that continuously monitors patients remotely. The company looks to market the device first in France and Germany.
Amber Therapeutics Ltd. revealed positive data from the first-in-human investigation of its Amber-UI device, an implantable closed-loop bioelectrical therapy for urinary incontinence. Initial results highlight the safety and scalability of the Amber-UI therapy, which has the potential to meaningfully improve quality of life for patients dealing with the condition.
In a sign that Royal Philips NV is not letting the problems in its business in the U.S. stop its innovation, the company has launched the Azurion neuro biplane, a new image guided therapy system for patients suffering from stroke and other neurovascular diseases. It also teamed up with Syntheticmr AB and launched Smart Quant Neuro 3D, an AI imaging tool which will help health care professionals diagnose and assess brain disorders like multiple sclerosis, traumatic brain injury and dementia.
Mainstay Medical Holdings plc raised $125 million in equity financing which it will use to conduct clinical trials and continue the commercial roll out of its Reactiv8 neurostimulation therapy that treats chronic lower back pain.
The $110 million that Medical Microinstruments Inc. (MMI) recently raised in its series C funding round is testament to its unique position in microsurgery, said Olivier Litzka, a board member at MMI and a partner at Andera Partners. “There are not many companies actually working in that space in robotics,” he told BioWorld.
Woven Orthopedic Technologies LLC secured a second U.S. FDA 510(k) clearance for the use of its Ogmend implant enhancement system in spine surgery. The approval is for the large size Ogmend sleeve which is compatible with pedicle screws up to 10.5 mm and will give surgeons a tool to be able to easily secure stable fixation between the screw and bone during orthopedic surgery.
Early-stage health care companies developing breakthrough medical technologies were given some good news recently with the launch of a new accelerator program by Israel’s Arc Innovation aimed at giving startups a $250,000 cash injection. With a $10 million investment from Ilex Medical Ltd., the initiative is looking to empower early-stage companies by providing financial backing, expert guidance and a support network.
Vessi Medical Ltd. recently closed a series A financing round at $16.5 million for the advancement of its cryotherapy technology to treat non-muscle invasive bladder cancer (NMIBC). Vessi believes that its minimally invasive device can provide a therapeutic alternative to a transurethral resection of bladder tumor (TURBT) procedure, the current first line therapy to treat the disease.
The U.K.’s National Institute for Health and Care Excellence (NICE) has given people looking to lose weight another treatment option by recommending endoscopic sleeve gastroplasty (ESG) as a therapy to help treat obesity. The move comes amidst increasing awareness of the disease brought on by the growing prevalence of GLP-1 agonists.
The €173 million (US$187 million) in capital that Earlybird Health recently raked in from investors will go towards bolstering investment in European health care startups, many of which are still recovering from the impact of COVID-19, Thom Rasche, a partner at Earlybird Health, told BioWorld. The fund is looking to invest in the technologies that can improve patient care.
